Vera Therapeutics (VERA) Market and Investor Communications Update
Market Performance (24‑Hour Period Ending 06:01 PM CET, Wednesday 21 Oct 2026)
- Share price increased by 3.94 % to USD 30.88.
- Outstanding shares: 71.9 million.
- Market capitalization: USD 2.10 billion.
- Trading volume over the last 24 hours: USD 35.8 million.
- Share price change since the end of the previous month: ‑12.23 %.
- Simple moving average (200 days): USD 37.67.
- 52‑week high: USD 56.05 (24 Dec 2025).
- 52‑week low: USD 23.05 (06 Nov 2025).
Upcoming Investor Webcasts
- 10 Oct 2026, 4:30 p.m. ET – Final efficacy analysis of TRUTAKNA from the ORIGIN 3 trial for IgA nephropathy patients.
- Presentation will cover results released as a late‑breaking oral at ASN Kidney Week 2026.
- TRUTAKNA is a BAFF and APRIL inhibitor that received accelerated approval for reducing proteinuria in adults at risk of disease progression.
- The webcast will address the drug’s safety profile, including infection risks and local injection reactions, and will review the patient support program facilitating access and coverage.
- 5 Nov 2026, 4:30 p.m. ET – Third‑quarter 2026 financial results and business updates.
- Management will provide live commentary and a Q&A session for investors.
Related Stock Performance (Last 24 Hours)
| Ticker | Change | Price (USD) | Market Cap (USD) | P/E Ratio |
|---|---|---|---|---|
| ADMA (Adma Biologics) | +1.45 % | 11.11 | 2.5 bn | 15.83 |
| FIVN (Five9 Inc.) | +2.91 % | 35.52 | 2.5 bn | 48.12 |
| GPK (Graphic Packaging) | +0.83 % | 8.39 | 2.5 bn | 12.83 |
| BKV (Bkv) | –0.13 % | 22.44 | 2.5 bn | – |
| TMDX (Transmedics) | +4.40 % | 73.58 | 2.5 bn | 17.85 |
Company Overview Vera Therapeutics, Inc. is a clinical‑stage biotechnology company headquartered in South San Francisco, United States. The company develops and commercializes treatments for serious immunological diseases. Vera Therapeutics trades on the NASDAQ exchange and provides information through its website at www.veratx.com .
